Table 2.

Secondary end points in EMPOWER CAD study.

Secondary end points •Angiographic success defined as stent delivery with ≤30% residual stenosis and without serious angiographic complications. •Procedural success defined as stent delivery with a residual stenosis <50% in all target lesions (core laboratory assessed) and without in-hospital TLF. •Angiographic success defined as stent delivery with <50% residual stenosis and without serious angiographic complications. •Serious angiographic complications defined as severe dissection (type D to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow. •TLF at 1, 2, and 3 y. •Major adverse cardiac events (MACE) defined as a composite of cardiac death, myocardial infarction (per SCAI definition for periprocedural MI; per Fourth Universal Definition for spontaneous MI beyond discharge), and target vessel revascularization (TVR) at 30 days and 1, 2 and 3 y. •At each period: all-cause death, cardiac-related death, MI, TV-MI, procedural and nonprocedural MI, ID-TVR, ID-TLR, ID-non-TLR, ID-non-TVR, all revascularizations (ID and non-ID), and stent thrombosis (Academic Research Consortium definite, probable, definite or probable). •MI rates and all composite end points (TLF, MACE) will also be reported using the Fourth Universal definition for periprocedural and spontaneous MI at all time points. •Angina symptoms assessed by Seattle Angina Questionnaire (SAQ-7) as a change from baseline (at each period). •Quality of life assessed by EQ-5D-5L as a change from baseline (at each period). •Quality of life assessed by Generalized Anxiety Disorder Questionnaire (GAD-7) as a change from baseline (at each period).

CAD, coronary artery disease; ID, ischemia driven; MI, myocardial infarction; TLF, target lesion failure.